Orpheus Uranium Limited

ORP

Orpheus Uranium Ltd. engages in the exploration and development of minerals including gold and copper. The company is headquartered in Adelaide, South Australia. The firm is focused on uranium exploration in the two jurisdictions of Australia that permit uranium mining, South Australia and the Northern Territory. In South Australia there are five key project areas: Frome, Mundaerno, Radium Hill South, Cummins and Marree. In the Northern Territory there are four key project areas: Mount Douglas, Woolner, Alligator Rivers Uranium Field and South Alligator Valley Mineral Field. Its other projects include Higginsville, Kroombit, Aroona, Lumwana West, Kamapanda, Kalaba East, Musangila, and others. The Frome project comprises four exploration licenses covering a combined area of 3,037 square kilometers, located in the Frome Embayment of South Australia. The Mundaerno project comprises one exploration license application, EL 6958, which comprises two blocks in the Southern Curnamona Province of South Australia.

Oncosil Medical Ltd

OSL

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.